Kathleen Sedgley is the Bristol BioDesign Institute Scientific Manager. She oversees the coordination of the synthetic and engineering biology portfolio across the University of Bristol and the underpinning partnerships.

She manages several high value and strategic BBI projects including UKRI-funded BrisEngBio, the Max Planck Bristol Centre for Minimal Biology and the ADDovenom EU Future Emerging Technologies Consortium.

Kathleen has a background in pharmacology and neuroendocrinology, and has over 15 years experience in research management.

She is an active member of the UK synthetic and engineering biology research managers network and has been instrumental in supporting the delivery of Bristol’s vision to be a world leading institution for synthetic and engineering biology research and innovation.